The EPO published patent application EP3853233A1 filed by Nikang Therapeutics covering tri-substituted heteroaryl compounds as SH2 phosphatase inhibitors for anti-cancer therapeutics. The application names inventors Fu Jiping, Lou Yan, and He Yigang, with the compounds classified under multiple IPC codes including C07D 519/00, C07D 491/10, C07D 401/14, A61P 35/00, and A61K 31/5383.\n\nPatent publications do not impose compliance obligations on third parties. No action is required from pharmaceutical manufacturers or researchers working in this therapeutic area unless they are pursuing similar patent claims that may conflict with the Nikang Therapeutics intellectual property rights. Companies developing SH2 phosphatase inhibitors should review this publication for potential freedom-to-operate considerations.